Miromatrix Medical Inc (MIRO) Peer Comparison

$3.39

$0.00 (0.00%)

As on 22-Dec-2023 09:30EDT

Market cap

$93 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

--

P/B Ratio

6

Div. Yield

0 %

Edit

	Miromatrix Medical Inc (MIRO)	Acer Therapeutics Inc. (DE) (ACER)	Neoleukin Therapeutics (NLTX)	Seagen (SGEN)
Market cap ($ Mln)	93	16	8	43,155
Revenue ($ Mln)	1	0	--	2,300
Net Profit ($ Mln)	-27.12	-60.92	-39.36	-750.23
Net Margin (%)	-2,430.11	1,778.97	281,135.71	-32.61
RoE (%)	-125.15	--	-54.63	-28.45
Price to Earnings	--	--	--	--
Price-To-Book	5.98	17.26	0.44	16.92

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Miromatrix Medical Inc (MIRO)	Acer Therapeutics Inc. (DE) (ACER)	Neoleukin Therapeutics (NLTX)	Seagen (SGEN)
Operating Revenue	0.96	0.37	0.00	2,300.35
Cost of Revenue	0.50	0.08	3.42	565.99
Gross Profit	0.45	--	--	1,552.35
Operating Expenses	28.94	27.71	34.60	2,524.93
Operating Profit (EBIT)	-28.48	-17.01	-38.02	-790.58
Other Income	0.16	-3.80	-0.01	0.00
Profit before Tax	-27.41	-48.49	-34.26	-738.94
Provision for Tax	0.07	17.23	5.10	11.29
Profit after Tax (Net Income)	-27.12	-60.92	-39.36	-750.23
Minority Interest	0.00	0.00	0.00	0.00
Consolidated Profit	-6.53	-8.09	-29.73	-534.44

Liabilities ($ Mln)

	Miromatrix Medical Inc (MIRO)	Acer Therapeutics Inc. (DE) (ACER)	Neoleukin Therapeutics (NLTX)	Seagen (SGEN)
Shareholder's Funds	15.54	-47.74	75.24	2,550.42
Minority Interest	0.00	0.00	0.00	0.00
Non-Current Liabilities	2.91	76.69	9.14	129.12
Current Liabilities	4.97	61.67	5.21	954.72
Total Liabilities	34.76	11.62	115.95	3,674.53

Assets ($ Mln)

	Miromatrix Medical Inc (MIRO)	Acer Therapeutics Inc. (DE) (ACER)	Neoleukin Therapeutics (NLTX)	Seagen (SGEN)
Non-Current Assets	6.23	7.86	9.69	1,082.67
Current Assets	17.19	6.14	79.89	2,551.59
Total Assets	34.76	11.62	115.95	3,674.53
Total Debt*	3.22	18.15	10.69	113.49
Net Current Assets	12.23	0.00	74.68	1,596.88

Cashflow ($ Mln)

	Miromatrix Medical Inc (MIRO)	Acer Therapeutics Inc. (DE) (ACER)	Neoleukin Therapeutics (NLTX)	Seagen (SGEN)
Cash From Operating Activities	-26.68	-30.25	-45.61	-453.75
Cash Flow from Investing Activities	--	--	-59.13	228.24
Cash from Financing Activities	0.17	20.04	0.16	125.36
Net Cash Inflow / Outflow	--	--	--	-100.15

Ratios

Profitability Ratios

	Miromatrix Medical Inc (MIRO)	Acer Therapeutics Inc. (DE) (ACER)	Neoleukin Therapeutics (NLTX)	Seagen (SGEN)
ROCE (%)	-70.93	894.87	-42.72	-20.45
ROE (%)	-125.15	301.44	-54.63	-28.45
ROA (%)	-74.25	-216.56	-33.99	-16.79
EBIT Margin (%)	-2,935.30	-3,716.22	--	-35.02
Net Margin (%)	-2,430.11	1,778.97	281,135.71	-32.61
Cash Profit Margin (%)	0.00	-0.42	--	0.00

Growth Ratios

	Miromatrix Medical Inc (MIRO)	Acer Therapeutics Inc. (DE) (ACER)	Neoleukin Therapeutics (NLTX)	Seagen (SGEN)
Revenue Growth (%)	2,978.99	3.28	-1.00	23.40
EBIT Growth (%)	2.07	41.93	36.65	-24.40
Net Profit Growth (%)	4.64	-188.48	32.57	-17.82
EPS Growth (%)	30.11	-105.96	-34.12	-15.72
Book Value Growth (%)	-63.08	-160.75	-29.11	-11.22

Valuation Ratios

	Miromatrix Medical Inc (MIRO)	Acer Therapeutics Inc. (DE) (ACER)	Neoleukin Therapeutics (NLTX)	Seagen (SGEN)
Price / Earnings	-2.09	-1.44	-0.50	-39.18
Price / Book Value	2.41	-2.40	0.30	8.53
Dividend Yield (%)	--	--	--	--
EV/EBITDA	-1.38	-2.00	0.99	-35.64
Market Cap ($ Cr)	--	--	--	--

Solvency Ratios

	Miromatrix Medical Inc (MIRO)	Acer Therapeutics Inc. (DE) (ACER)	Neoleukin Therapeutics (NLTX)	Seagen (SGEN)
Debt to Equity	0.02	0.00	0.00	0.00
Short term debt to equity ratio	0.03	-0.38	0.02	0.00
Current Ratio	3.46	0.10	15.33	2.67
Quick Ratio	3.30	0.02	15.33	2.12
Interest Coverage	-589.56	-41.48	-11.56	-7.03

Operating Efficiency Ratios

	Miromatrix Medical Inc (MIRO)	Acer Therapeutics Inc. (DE) (ACER)	Neoleukin Therapeutics (NLTX)	Seagen (SGEN)
Debtors to sales (%)	9.46	0.00	--	27.45
Asset Turnover	0.03	0.01	0.00	0.51
Receivable days	443.02	--	--	82.93
Inventory Days	584.47	--	--	279.63
Payable days	1,344.04	--	--	143.71
Cash Conversion Cycle	-316.54	--	--	218.86

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly